CRISPR Therapeutics
CRISPR Therapeutics, co-founded by Nobel laureate Emmanuelle Charpentier, is a leading biotechnology company dedicated to developing transformative gene-based medicines using its proprietary CRISPR/Cas9 platform. The company achieved a landmark success in collaboration with Vertex Pharmaceuticals, receiving the first-ever regulatory approval for a CRISPR-based gene therapy, CASGEVY™ (exagamglogene autotemcel), for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia. This groundbreaking *ex vivo* therapy works by editing a patient’s own blood stem cells to turn on fetal hemoglobin expression, offering a potential cure for serious hemoglobinopathies. Beyond this monumental achievement, CRISPR Therapeutics maintains a robust and diverse pipeline of programs, including allogeneic CAR-T cell therapies for oncology, *in vivo* gene editing for cardiovascular and neurological disorders, and cell therapies for diabetes. Their continuous innovation aims to push the boundaries of science and broaden the applications of CRISPR technology across a wide range of debilitating human diseases, solidifying their position at the forefront of the gene editing revolution.
Latest Market Research Report on Gene Editing Download PDF Brochure Now
Intellia Therapeutics
Intellia Therapeutics, co-founded by Nobel laureate Jennifer Doudna, is a clinical-stage biotechnology company focused on developing curative gene editing treatments using its CRISPR/Cas9 technology. The company pursues a dual strategy: *in vivo* therapies, which edit cells directly inside the body using lipid nanoparticles (LNPs) to deliver the CRISPR components, and *ex vivo* cell therapies for specific diseases. Intellia achieved a major first by demonstrating the potential of systemic *in vivo* CRISPR editing in a clinical trial for transthyretin amyloidosis (ATTR), where a single intravenous infusion was shown to reduce disease-causing protein levels. Their wholly-owned late-stage candidate, NTLA-2002, is an *in vivo* therapy for hereditary angioedema (HAE). Additionally, Intellia is advancing programs in collaboration with large pharmaceutical partners like Regeneron, targeting hemophilia B and other genetic conditions. By pioneering the safe and effective use of CRISPR technology within the body, Intellia is committed to translating the profound potential of gene editing into durable, life-changing medicines for people living with severe and life-threatening genetic diseases.
Beam Therapeutics
Beam Therapeutics is a pioneering biotechnology company focused on creating a new class of precision genetic medicines using its proprietary base editing technology. Base editing is a next-generation CRISPR variant that functions like a “molecular pencil,” enabling precise changes to single base pairs (DNA or RNA letters) without cutting both strands of the DNA helix, which may reduce certain safety risks associated with traditional CRISPR/Cas9 double-stranded breaks. The company’s vision is to provide lifelong cures to patients suffering from serious diseases through highly targeted genetic modifications. Beam’s pipeline includes several programs for hematological disorders, such as a base editing therapy (BEAM-101) for sickle cell disease, which aims to turn on fetal hemoglobin production. Their technologies are being designed to offer various types of modifications, including gene activation, gene knock-out, and gene correction, across both *in vivo* and *ex vivo* approaches. By focusing on base editing’s precision and versatility, Beam Therapeutics is a key innovator driving the evolution of gene editing beyond conventional methods.
Editas Medicine
Editas Medicine is a clinical-stage genome editing company committed to translating the potential of CRISPR/Cas9 and CRISPR/Cas12a systems into a robust pipeline of treatments for genetically determined disorders. The company’s foundational work centers on repairing disease-causing genes with high precision, focusing on both *in vivo* and *ex vivo* approaches. Editas has been a pioneer in using the Cas12a protein in clinical trials, notably in a phase 1/2 trial for severe sickle cell disease and transfusion-dependent beta-thalassemia, similar to the approved Casgevy mechanism of turning on fetal hemoglobin expression. Their pipeline includes efforts in inherited retinal diseases, such as the EDIT-101 program. Editas Medicine is also exploring applications in oncology and other genetically determined disorders, often leveraging its proprietary technologies through strategic alliances and collaborative product development. By continuously optimizing its genomic editing tools, including the use of both Cas9 and the less-known but equally powerful Cas12a, Editas aims to develop next-generation genomic medicines that offer durable therapeutic solutions for people living with serious and often rare diseases.
Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company that has become a critical player in the gene editing landscape through its strategic partnership with CRISPR Therapeutics. While primarily known for its marketed therapies for cystic fibrosis, Vertex played an instrumental role in the clinical development and commercialization of the revolutionary gene-edited therapy, CASGEVY™ (exagamglogene autotemcel). Vertex’s significant operational capabilities, regulatory expertise, and financial commitment were essential in advancing Casgevy—the first FDA-approved medicine based on CRISPR technology—from the lab to patients with sickle cell disease and beta-thalassemia. Vertex continues to deepen its involvement in genetic medicines by collaborating on the development of other gene editing and cell therapy programs. This strategic focus ensures that they remain at the forefront of genetic medicine delivery, leveraging their commercial infrastructure to make complex, potentially curative, gene editing treatments accessible to patients globally. Their successful collaboration underscores the importance of large biopharma partnerships in translating groundbreaking gene editing science into commercial reality.
Caribou Biosciences
Caribou Biosciences is a clinical-stage biotechnology company that stands out for its pioneering work in developing next-generation, genome-edited cell therapeutics using its innovative CRISPR-Cas platform. The company’s proprietary Cas12a chRDNA (CRISPR hybrid RNA-DNA) technology is a key differentiator, engineered to enable highly precise and complex genome edits while minimizing the risk of off-target effects. Caribou leverages this technology to create ‘off-the-shelf’ allogeneic cell therapies, primarily for the treatment of life-threatening diseases such as oncological and hematological disorders. Their approach involves using CRISPR-Cas to engineer T-cells (CAR-T) and natural killer (CAR-NK) cells with enhanced anti-tumor activity and greater longevity. By focusing on improving the safety and efficacy of cell therapies through precision gene editing, Caribou aims to make these transformative treatments more accessible, scalable, and safer for patients. The company’s commitment to advancing its chRDNA platform reinforces its prominent role among companies driving the development of complex, *ex vivo* gene editing applications.
Prime Medicine
Prime Medicine is a biotechnology company uniquely specialized in advancing the field of **prime editing**, a highly versatile and precise gene editing technique. Prime editing, which uses a guide RNA combined with a reverse transcriptase enzyme, is often described as a “search-and-replace” function for the genome. Unlike traditional CRISPR-Cas9, which creates a double-stranded break in the DNA, prime editing is capable of making all 12 possible single-base-pair changes and small insertions/deletions without breaking both strands. This precision is intended to minimize unwanted byproducts and off-target edits, addressing a key safety concern in gene editing. The company has a deep and growing pipeline of 18 programs targeting a wide range of severe genetic diseases, including cystic fibrosis, Duchenne muscular dystrophy, and Huntington’s disease. By focusing exclusively on this next-generation editing tool, Prime Medicine is positioning itself as a leader capable of correcting a vast majority of known disease-causing mutations, thereby accelerating the path toward potentially curative, non-disruptive genomic medicines.
Arcturus Therapeutics
Arcturus Therapeutics is a global RNA medicines company with a proprietary focus on developing innovative messenger RNA (mRNA) therapeutics and vaccines, which includes a strategy for gene editing applications. The company’s core technology involves its highly versatile lipid nanoparticle (LNP) platforms, LUNAR® and STARR™, which are critical for the efficient and safe delivery of therapeutic payloads like mRNA into target cells *in vivo*. Arcturus claims to leverage these advanced delivery systems to enable gene editing, gene silencing, and gene upregulation, often in the context of infectious diseases and certain genetic disorders. While much of their public-facing work has recently centered on mRNA vaccine development, their LNP technology provides the essential delivery vehicle for various gene editing tools, such as the components of CRISPR/Cas systems. By mastering the non-viral delivery of genetic material, Arcturus plays an important enabling role in the gene editing ecosystem, specifically by solving the challenge of safely transporting the complex machinery required for editing directly into the body’s cells.
Latest Market Research Report on Gene Editing Download PDF Brochure Now